Systemic lupus erythematosus natural history: Difference between revisions
Usama Talib (talk | contribs) |
Usama Talib (talk | contribs) |
||
| Line 25: | Line 25: | ||
The ANA is the most sensitive screening test for evaluation, whereas [[LSm#History|anti-Sm (anti-Smith)]] is the most specific. The dsDNA (double-stranded [[DNA]]) antibody is also fairly specific and often fluctuates with disease activity; as such, the dsDNA titer is sometimes useful to monitor disease flares or response to treatment.<ref>[Early steroids may prevent relapses in lupus, P Jarman (Published in Journal Watch (General) July 18, 1995)</ref> | The ANA is the most sensitive screening test for evaluation, whereas [[LSm#History|anti-Sm (anti-Smith)]] is the most specific. The dsDNA (double-stranded [[DNA]]) antibody is also fairly specific and often fluctuates with disease activity; as such, the dsDNA titer is sometimes useful to monitor disease flares or response to treatment.<ref>[Early steroids may prevent relapses in lupus, P Jarman (Published in Journal Watch (General) July 18, 1995)</ref> | ||
==References== | ==References== | ||
Latest revision as of 17:31, 19 July 2017
|
Systemic lupus erythematosus Microchapters |
|
Differentiating Systemic lupus erythematosus from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Systemic lupus erythematosus natural history On the Web |
|
American Roentgen Ray Society Images of Systemic lupus erythematosus natural history |
|
Directions to Hospitals Treating Systemic lupus erythematosus |
|
Risk calculators and risk factors for Systemic lupus erythematosus natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Overview
Natural History
Complications
Some people with SLE have abnormal deposits in the kidney cells. This leads to a condition called lupus nephritis. Patients with this condition may eventually develop kidney failure and need dialysis or a kidney transplant.
SLE causes damage to many different parts of the body, including:
- Blood clots in the legs (deep vein thrombosis) or lungs (pulmonary embolism)
- Destruction of red blood cells (hemolytic anemia) or anemia of chronic disease
- Fluid around the heart (pericarditis), endocarditis, or inflammation of the heart (myocarditis)
- Fluid around the lungs (pleural effusions) and damage to lung tissue
- Pregnancy complications, including miscarriage
- Stroke
- Severely low blood platelets (thrombocytopenia)
- Inflammation of the blood vessels
Prognosis
In the 1950s, most people diagnosed with SLE lived fewer than five years. Advances in diagnosis and treatment have improved survival to the point where over 90% now survive for more than ten years, and many can live relatively asymptomatically. Prognosis is normally worse for men and children than for women; however, if symptoms are present after age 60, the disease tends to run a more benign course. Early mortality, within 5 years, is due to organ failure or overwhelming infections, both of which can be modified by early diagnosis and treatment. The mortality risk is five-fold when compared to the normal population in the late stages, which can be attributed to cardiovascular diseases acquired from corticosteroid therapy. To reduce potential for cardiovascular issues, steroids should be used at the lowest dose for the shortest possible period. High serum creatinine, hypertension, nephrotic syndrome, anemia and hypoalbuminemia are poor prognostic factors.[1]
The ANA is the most sensitive screening test for evaluation, whereas anti-Sm (anti-Smith) is the most specific. The dsDNA (double-stranded DNA) antibody is also fairly specific and often fluctuates with disease activity; as such, the dsDNA titer is sometimes useful to monitor disease flares or response to treatment.[2]
References
- ↑ Poor prognostic factors,Sudheer, SLE document
- ↑ [Early steroids may prevent relapses in lupus, P Jarman (Published in Journal Watch (General) July 18, 1995)